PMID- 19294695
OWN - NLM
STAT- MEDLINE
DCOM- 20090818
LR  - 20181201
IS  - 1615-9861 (Electronic)
IS  - 1615-9853 (Linking)
VI  - 9
IP  - 7
DP  - 2009 Apr
TI  - Synergistic effect of trichostatin A and 5-aza-2'-deoxycytidine on growth 
      inhibition of pancreatic endocrine tumour cell lines: a proteomic study.
PG  - 1952-66
LID - 10.1002/pmic.200701089 [doi]
AB  - Our research group recently reported that pancreatic endocrine cancer cell lines 
      are sensitive to the HDAC inhibitor trichostatin A (TSA). In the present paper, 
      we show that the combined treatment of pancreatic endocrine tumour cell lines 
      with TSA and the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (DAC) 
      determines a strong synergistic inhibition of proliferation mainly due to 
      apoptotic cell death. Proteomic analysis demonstrates that the modulation of 
      specific proteins correlates with the antiproliferative effect of the drugs. A 
      schematic network clarifies the most important targets or pathways involved in 
      pancreatic endocrine cancer growth inhibition by single or combined drug 
      treatments, which include proteasome, mitochondrial apoptotic pathway and caspase 
      related proteins, p53 and Ras related proteins. A comparison between the patterns 
      of proteins regulated by TSA or DAC in endocrine and ductal pancreatic cancer 
      cell lines is also presented.
FAU - Cecconi, Daniela
AU  - Cecconi D
AD  - Dipartimento di Biotecnologie, Laboratorio di Proteomica, Universita di Verona, 
      Verona, Italy.
FAU - Donadelli, Massimo
AU  - Donadelli M
FAU - Dalla Pozza, Elisa
AU  - Dalla Pozza E
FAU - Rinalducci, Sara
AU  - Rinalducci S
FAU - Zolla, Lello
AU  - Zolla L
FAU - Scupoli, Maria Teresa
AU  - Scupoli MT
FAU - Righetti, Pier Giorgio
AU  - Righetti PG
FAU - Scarpa, Aldo
AU  - Scarpa A
FAU - Palmieri, Marta
AU  - Palmieri M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Proteomics
JT  - Proteomics
JID - 101092707
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Hydroxamic Acids)
RN  - 3X2S926L3Z (trichostatin A)
RN  - 776B62CQ27 (Decitabine)
RN  - M801H13NRU (Azacitidine)
SB  - IM
MH  - Analysis of Variance
MH  - Apoptosis/drug effects
MH  - Azacitidine/*analogs & derivatives/pharmacology
MH  - Carcinoma, Pancreatic Ductal/metabolism
MH  - Cell Cycle
MH  - Cell Line, Tumor
MH  - Cell Proliferation/*drug effects
MH  - Decitabine
MH  - Drug Synergism
MH  - Endocrine Gland Neoplasms/metabolism
MH  - Enzyme Inhibitors/*pharmacology
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation, Neoplastic/*drug effects
MH  - Humans
MH  - Hydroxamic Acids/*pharmacology
MH  - Pancreatic Neoplasms/*metabolism
EDAT- 2009/03/19 09:00
MHDA- 2009/08/19 09:00
CRDT- 2009/03/19 09:00
PHST- 2009/03/19 09:00 [entrez]
PHST- 2009/03/19 09:00 [pubmed]
PHST- 2009/08/19 09:00 [medline]
AID - 10.1002/pmic.200701089 [doi]
PST - ppublish
SO  - Proteomics. 2009 Apr;9(7):1952-66. doi: 10.1002/pmic.200701089.